OverviewSuggest Edit

Nordic Nanovector, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics in hematology and oncology. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. The Company has a collaboration agreement with AREVA Med and Paul Scherrer Institute to develop antibody-drug conjugates for treating leukaemias; and LegoChem Biosciences and Heidelberg Pharma to develop Antibody Radionuclide conjugates.

TypePublic
Founded2009
HQOslo, NO
Websitenordicnanovector.com

Latest Updates

Employees (est.) (Dec 2020)37(-15%)
Share Price (Jan 2021)KR14.1(-1%)
Cybersecurity ratingAMore

Key People/Management at Nordic Nanovector

Jean-Pierre Bizzari

Jean-Pierre Bizzari

Director
Rainer Boehm

Rainer Boehm

Director
Marco Renoldi

Marco Renoldi

Chief Operating Officer
Joanna Horobin

Joanna Horobin

Director
Jostein Dahle

Jostein Dahle

Chief Scientific Officer
Karin Meyer

Karin Meyer

Director
Show more

Nordic Nanovector Office Locations

Nordic Nanovector has offices in Oslo, Zug and Shrewsbury
Oslo, NO (HQ)
168 Kjelsåsveien
Zug, CH
10 Grafenauweg
Shrewsbury, GB
1 Brassey Rd
Show all (3)

Nordic Nanovector Financials and Metrics

Nordic Nanovector Revenue

Market capitalization (28-Jan-2021)

1.1b

Closing stock price (28-Jan-2021)

14.1
Nordic Nanovector's current market capitalization is kr1.1 b.
Show all financial metrics

Nordic Nanovector Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Nordic Nanovector Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Nordic Nanovector Online and Social Media Presence

Embed Graph

Nordic Nanovector News and Updates

Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer

OSLO, Norway, July 1, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that Ms. Malene Brondberg has been appointed interim Chief Executive Officer with immediate effect. Ms. Brondberg, who is currently the Company's Chief Financial Officer, replaces Peter Braun who has...

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)...

Nordic Nanovector ASA: Increase of share capital

OSLO, Norway, June 18, 2021 /PRNewswire/ -- The two US-based board members of Nordic Nanovector ASA (the "Company"), Joanna Horobin and Jean-Pierre Bizzari have resolved to settle a total number of 22,860 RSUs that were issued to them in June 2020 after they had elected to receive all or...

Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

OSLO, Norway, June 2, 2021 /PRNewswire/ -- Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2021 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units...

Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma

OSLO, Norway, May 25, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin® (177Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). The...

Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast

OSLO, Norway, May 20, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2021 on Wednesday, 26 May 2021. A presentation by Nordic Nanovector's senior management team will be webcast live the same day at 8:30am CET. The...
Show more

Nordic Nanovector Frequently Asked Questions

  • When was Nordic Nanovector founded?

    Nordic Nanovector was founded in 2009.

  • Who are Nordic Nanovector key executives?

    Nordic Nanovector's key executives are Jean-Pierre Bizzari, Rainer Boehm and Marco Renoldi.

  • How many employees does Nordic Nanovector have?

    Nordic Nanovector has 37 employees.

  • Who are Nordic Nanovector competitors?

    Competitors of Nordic Nanovector include WuXi AppTec, Acousia Therapeutics and BioSpecifics Technologies.

  • Where is Nordic Nanovector headquarters?

    Nordic Nanovector headquarters is located at 168 Kjelsåsveien, Oslo.

  • Where are Nordic Nanovector offices?

    Nordic Nanovector has offices in Oslo, Zug and Shrewsbury.

  • How many offices does Nordic Nanovector have?

    Nordic Nanovector has 3 offices.